Print page Resize text Change font-size Change font-size Change font-size High contrast


EMA systems unavailable from 20:00 Friday 30 October to 6:00 Tuesday 3 November

All European Medicines Agency (EMA) IT systems will be temporarily unavailable from 20:00 on Friday 30 October to 6:00 on Tuesday 3 November (UK time), due to an essential exercise to test the Agency’s IT recovery processes in case of a major event.
 During this period, it will not be possible to access the EMA public website,, or any other EMA-hosted website or online application, including the ENCePP website, EU PAS Register (E-Register of Studies), and the ENCePP resources database. Normal service will resume on 3 November.
Emails sent to EMA email addresses during this period will be queued and delivered to recipients on 3 November.
We would like to thank you in advance for your patience and cooperation during this essential IT maintenance work.




About ENCePP

Find out more about the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance.


Are you a company seeking to commission or collaborate in the conduct of a post-authorisation study (PAS)?

Find out more

Do you wish to register a study in the EU PAS Register?

Find out more

Are you considering applying for an ENCePP study seal?

Read a personal account of the ENCePP study approval process

Are you interested in the recommendations from the European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) on safety signals?

Review the list of signals discussed




Latest News
2 October 2015
Public consultation: CIOMS Ethical Guidelines for Biomedical Research Involving Human Subjects

The CIOMS Working Group on the Revision of CIOMS 2002 International Ethical Guidelines for Biomedical Research Involving Human Subjects has completed a draft revision of these updated guidelines and has published them on the website of CIOMS for consultation. The consultation will be open for comments until 1 March 2016.


Related information:

» Further information from CIOMS

» CIOMS Guidelines - Public Consultation

29 September 2015
ADVANCE Code of Conduct for public consultation

The Accelerated Development of VAccine benefit-risk Collaboration in Europe

(ADVANCE) is a a public-private partnership supported by the Innovative Medicines Initiative in order to establish a scientific and transparent framework for the rapid monitoring of the benefits and risks of marketed vaccines. For this purpose, ADVANCE is developing a Good practice guidance with a Code of Conduct for the planning, initiation, design, conduct and reporting of observational studies in the field of vaccines. The Code of Conduct will also support interactions between different parties involved in studies on vaccines and provide confidence to health professionals and the public about the quality of their results.

ADVANCE has launched a public consultation of the draft Code of Conduct until 15th November 2015.


Related information:

» ADVANCE website


More news ...